Bioprinting is 20 Years Old: Lessons Learned
Gabor Forgacs, Professor, University of Missouri-Columbia; Founder, Modern Meadow
Bioprinting* has seen spectacular progress in the last two decades, both in academia and commercially. The number of researchers devoted to the topic and commercial entities in the space have grown dramatically. Publications on the topic have been multiplying exponentially. However, as with most new technologies, due to the unavoidable hype, expectations have been set unrealistically high. This talk will attempt to separate hype from reality, motivated by the desire to place the field in the right perspective. This will be done by first briefly overviewing some of the field’s most remarkable accomplishments, using proven applications in pharmaceutic and therapeutics as illustrative examples. Finally, an unbiased view on what bioprinting realistically might accomplish in the future will be presented, as much as this is possible by someone who has been involved in the field since its birth.
*For the purposes of this talk, bioprinting is defined as a version of 3D printing with live material, such as cells.
|
|